ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Juvenile idiopathic arthritis"

  • Abstract Number: 0413 • ACR Convergence 2024

    Efficacy of Intra-articular Glucocorticoids as a Treatment for Oligoarticular Juvenile Idiopathic Arthritis: A Bicentric Retrospective Study in Japan

    Keiji Akamine1, Mao Mizuta2, Reiko Yatabe1, Yukari Aida3, Naoaki Mikami1, Ryoko Harada1, Riku Hamada1, Yasuo Nakagishi3 and Hiroshi Hataya1, 1Department of Nephrology and Rheumatology, Tokyo Metropolitan Children’s Medical Center, Fuchu, Tokyo, Japan, 2Department of Pediatric Rheumatology, Hyogo Prefectural Kobe Children’s Hospital, Kanazawa, Hyogo, Japan, 32) Department of Rheumatology, Hyogo Prefectural Kobe Children’s Hospital, Kobe, Hyogo, Japan

    Background/Purpose: Intra-articular glucocorticoids (IAGCs), a treatment for oligoarticular JIA, is a local therapy that obviates the need for systemic medication and its attendant side effects…
  • Abstract Number: 1761 • ACR Convergence 2024

    Juvenile Idiopathic Arthritis Genetic Risk Haplotypes: Relevance to Children of African Ancestry

    Sabrina George1, Hannah C Ainsworth2, Kaiyu Jiang3, Gilad Barshad4, Adam He4, Edward Rice4, Carl D Langerfeld2, Charles G Danko4 and James N Jarvis3, 1University at Buffalo Jacobs School of Medicine, Buffalo, NY, 2Wake Forest University, Winston-Salem, NC, 3University of Washington School of Medicine, Seattle, WA, 4Cornell University Baker School of Veterinary Medicine, Ithaca, NY

    Background/Purpose: - Numerous juvenile idiopathic arthritis (JIA) risk loci have been identified, overwhelmingly from cohorts of children of European ancestry (EA). The extent to which…
  • Abstract Number: 2653 • ACR Convergence 2024

    Impact of Insurance on Time to Biological Drug (bDMARD) Initiation and Inactive Disease Achievement in Patients with Juvenile Idiopathic Arthritis

    Elaine Yung1, Xiaoxuan Liu2, Bin Huang3, Michael Wagner1, Minal Aundhia2, Chen Chen4 and hermine brunner5, 1Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 2Cincinnati Children's Hospital Medical Center, Cincinnati, 3Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cinciannati, OH, 4Cincinnati Children's Hospital Medical Center, Cin, OH, 5Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, OH

    Background/Purpose: When uncontrolled, JIA is associated with short-term and long-term complications that affect the patient’s quality of life.  A common goal of treatment is to…
  • Abstract Number: 0390 • ACR Convergence 2024

    Treatment Effectiveness Following Switching from Initial TNF Inhibitor in Juvenile Idiopathic Arthritis

    Mei-Sing Ong1, Sarah Ringold2, Melissa Mannion3, Marc Natter4 and Yukiko Kimura5, 1Harvard Medical School & Harvard Pilgrim Healthcare Institute, Boston, MA, 2Washington University, Seattle, 3University of Alabama at Birmingham, Birmingham, AL, 4Boston Children's Hospital, Boston, MA, 5Hackensack Meridian School of Medicine, New York, NY

    Background/Purpose: Although the increasing availability of biologic therapies has significantly improved outcomes for patients with JIA, a substantial proportion of patients require switching from the…
  • Abstract Number: 0415 • ACR Convergence 2024

    Prevalence and Risk Factors of Low Bone Mineral Density in Children with Juvenile Idiopathic Arthritis

    narendra bagri, Sushain Kalsotra, vandana jain, Manisha Jana, Maroof Ahmed Khan, Yashdeep Gupta and Sumit Kumar Das, All India Institute of Medical Sciences, New Delhi, Delhi, India

    Background/Purpose: Juvenile idiopathic arthritis (JIA) is the most common chronic rheumatological disease in children less than 16 years of age. Various factors have been suggested…
  • Abstract Number: 1765 • ACR Convergence 2024

    CD8+ T Cells and Monocytes from Children with Macrophage Activation Syndrome Demonstrate Specific Transcriptional Changes Consistent with T Cell Activation and Expansion of Monocytes Shaped by Interferon and TLR Signaling

    Susan Canny1, Hannah DeBerg2, Griffin Gessay2, Ailing Lu3, Mary Eckert4, Andrea La Bella5, Hayley Waterman2, Danish Nadeem2, Susan Shenoi6, Joyce Hui-Yuen7, Daniel Campbell2, Betsy Barnes8 and Jessica Hamerman2, 1University of Washington, Seattle, WA, 2Benaroya Research Institute, Seattle, WA, 3Northwell Health, Manhasset, NY, 4Seattle Children's Hospital, Seattle, WA, 5Cohen Children's Medical Center, Queens, NY, 6Seattle Children's Hospital and Research Center, Mercer Island, WA, WA, 7North Shore LIJ Health System, Great Neck, NY, 8Feinstein Institutes for Medical Science, Manhasset, NY

    Background/Purpose: Macrophage activation syndrome (MAS), a form of secondary hemophagocytic lymphohistiocytosis (sHLH), is a potentially fatal complication of rheumatic diseases. MAS is characterized by a…
  • Abstract Number: 0392 • ACR Convergence 2024

    Evaluation for the Presence of Antibodies to Malondialdehyde-Acetaldehyde Adduct in Juvenile Idiopathic Arthritis and Its Subtypes

    Geoffrey Thiele1, Panteha Hayati Rezvan2, Michal Cidon2, Carlos Hunter3, Michael Duryee3, Ted Mikuls3 and Geoffrey Thiele3, 1Children's Hospital of Los Angeles, Omaha, NE, 2Children's Hospital of Los Angeles, Los Angeles, CA, 3University of Nebraska Medical Center, Omaha, NE

    Background/Purpose: Studies of rheumatoid arthritis (RA) have shown that malondialdehyde-acetaldehyde (MAA) protein adducts and anti-MAA immune responses play a pathogenic role in disease progression. Expression of…
  • Abstract Number: 0416 • ACR Convergence 2024

    Proteomic Signatures of Synovial Fluid in Different Subtypes of Juvenile Idiopathic Arthritis

    narendra bagri1, saumya srivastava2, yogendra singh2, Thirumurthy Velpandian2, Ashish Upadhyay2, venkatesan sampath kumar2, Subhradip Karmakar2 and sushil K Kabra2, 1All India Institute of Medical Sciences, New Delhi, Delhi, India, 2AIIMS New Delhi, new delhi, India

    Background/Purpose: Juvenile Idiopathic Arthritis (JIA) is heterogenous group of inflammatory disorder with clinically distinct subtypes; polyarticular, oligoarticular systemic onset JIA (sJIA), and enthesitis-related arthritis (ERA).…
  • Abstract Number: 1768 • ACR Convergence 2024

    A Potential Role of Longstanding IL-18 Stimulation in the Susceptibility for Macrophage Activation Syndrome in Patients with Systemic Juvenile Idiopathic Arthritis

    Greta Rogani1, Remco Erkens1, Marein Putmans1, Rianne Scholman1, Jorg van Loosdregt2 and Sebastiaan Vastert1, 1University Medical Center Utrecht, Utrecht, Netherlands, 2University Medical Center Utrecht, La Jolla, CA

    Background/Purpose: Macrophage Activation Syndrome (MAS) is a pathologic condition of immune hyperactivation, which occurs in 10-30% of cases of Still’s Disease (SD), the spectrum of…
  • Abstract Number: 0394 • ACR Convergence 2024

    Unveiling Major Challenges and Unmet Needs in the Therapeutic Approach to Systemic Juvenile Idiopathic Arthritis: The Patient Perspective

    Francesco Baldo1, Luciana Peixoto2, Remco Erkens3, Greta Rogani3, Claudia Bracaglia4, Dirk Foell5, Marco Gattorno6, Marija Jelusic7, Sebastiaan Vastert3, Rashmi Sinha2 and Francesca Minoia8, and on behalf of the PReS MAS/sJIA Working Party and the Systemic JIA Foundation, 1Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy, 2Systemic JIA Foundation, Cincinnati, OH, 3University Medical Center Utrecht, Utrecht, Netherlands, 4IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy, 5University Hospital Muenster, Muenster, Germany, 6IRCCS Giannina Gaslini, Genoa, Italy, 7University of Zagreb School of Medicine, University Hospital Centre Zagreb, Zagreb, Zagreb, Croatia, 8Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano, Milan, Italy

    Background/Purpose: Despite continuous improvements in the therapeutic options for children with systemic juvenile idiopathic arthritis (sJIA), access to medications significantly differs among centres and countries.…
  • Abstract Number: 0419 • ACR Convergence 2024

    Placental Weights of Offspring Born to Women with Rheumatoid Arthritis and Juvenile Idiopathic Arthritis

    Eugenia Chock1, Zeyan Liew2, Lars Henning Pedersen3 and Mette Oestergaard Thunbo3, 1Yale School of Medicine, New Haven, CT, 2Yale Center for Perinatal, Pediatric and Environmental Epidemiology, New Haven, CT, 3Aarhus University, Aarhus, Denmark

    Background/Purpose: Offspring of patients with chronic inflammatory arthritis have almost double the risk of being born small for gestational age. Placental insufficiency is one of…
  • Abstract Number: 1778 • ACR Convergence 2024

    A Novel Variant in IRAK2 Results in Immune Dysregulation in Systemic Juvenile Idiopathic Arthritis (sJIA)

    Mariana Correia Marques1, Brooke Boyd2, Alana Platukus3, Elizabeth Schmitz2, Hiroto Nakano2, Faiza Naz4, Anthony Cruz1, Stefania Dell'Orso4, Zuoming deng4 and Michael Ombrello5, 1National Institutes of Health, Bethesda, MD, 2Translational Genetics and Genomics Section, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, Bethesda, MD, 31Translational Genetics and Genomics Section, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, Bethesda, MD, 4National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD, Bethesda, MD, 5National Institute of Arthritis and Musculoskeletal and Skin Diseases, Bethesda, MD

    Background/Purpose: Lung disease (LD) is poorly understood complication of Still’s disease with high fatality. HLA-DRB1*15 is a strong risk factor for the development of this…
  • Abstract Number: 0376 • ACR Convergence 2024

    Preliminary Results of the Ondansetron Pre-medication Trial in Juvenile Idiopathic Arthritis: A Pragmatic Randomized Controlled Trial Nested in the CAPRI Registry

    Gaelle Chedeville1, Heinrike Schmeling2, Jean-Philippe Proulx-Gauthier3, Michelle Batthish4, Jean Jacques De Bruycker5, Brian Feldman6, Roberta A Berard7, Roxana Bolaria8, Amieleena Chhabra9, Lily Lim10, Adam Huber11, Matthew Berkowitz12, Thomas Loughin12 and Jaime Guzman13, and CAPRI Registry Investigators, 1The Montreal Children's Hospital, Montreal, QC, Canada, 2University of Calgary, Calgary, AB, Canada, 3CHU de Quebec - Universite Laval, Quebec, QC, Canada, 4McMaster Children's Hospital, Hamilton, ON, Canada, 5UNIVERSITY OF MONTREAL, Montreal, QC, Montreal, QC, Canada, 6Division of Rheumatology, The Hospital for Sick Children; Departments of Pediatrics and Medicine, Faculty of Medicine; The Institute for Health Policy, Management and Evaluation, Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada, 7London Health Sciences Centre, London, ON, Canada, 8Victoria Arthritis Center, Victoria, BC, Canada, 9University of British Columbia, Penticton, BC, Canada, 10University of Manitoba, Winnipeg, MB, Canada, 11IWK Health Centre, Halifax, NS, Canada, 12Simon Fraser University, Burnaby, BC, Canada, 13University of British Columbia and BC Children's Hospital, Vancouver, BC, Canada

    Background/Purpose: About 50% of children with Juvenile Idiopathic Arthritis (JIA) receiving methotrexate (MTX) develop MTX intolerance with severe anticipatory nausea/vomiting and avoidance behaviors. Intolerance often…
  • Abstract Number: 0395 • ACR Convergence 2024

    Assessment of Enthesitis by Pediatric Rheumatology Providers

    Erin Treemarcki1, Shirley Tse2, Marisa Klein-Gitelman3, Adam Mayer4, Hemalatha Srinivasalu5, Heather Walters6 and Melissa Oliver7, and the CARRA Juvenile Spondyloarthritis Workgroup and the CARRA investigators, 1University of Utah, Salt Lake City, UT, 2SickKids, Toronto, ON, Canada, 3Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, 4University of Pennsylvania/Children's Hospital of Philadelphia, Philadelphia, PA, 5Children's National Hospital, Washington, DC, 6Northwell Health, New Hyde Park, NY, 7Indiana University, Indianapolis, IN

    Background/Purpose: Enthesitis is a characteristic feature of enthesitis related arthritis (ERA) but can be found in other juvenile idiopathic arthritis (JIA) subtypes. It occurs with…
  • Abstract Number: 0779 • ACR Convergence 2024

    Sex Differences in the B Cell Compartment of Patients with Oligoarticular Juvenile Idiopathic Arthritis

    Ki Pui Lam1, Claudia Harris1, Daniela Fernandez-Salinas1, Maryrose Hahn2, Maryam Ashoor3, Ahmad Bakhsh1, Carrie Bryant1, Siobhan Case1, Mia Chandler4, Joyce Chang5, Ezra Cohen1, Fatma Dedeoglu3, Olha Halyabar1, Jonathan Hausmann1, Melissa Hazen3, Daniel Ibanez1, Liyoung Kim1, Jeffrey Lo3, Mindy Lo3, Esra Meidan6, Megan Perron1, Helene Powers1, Mary Beth Son5, Holly Wobma7, Pui Lee8, Peter Nigrovic5, Laurie Ohlms9, Margaret Chang3, Maria Gutierrez-Arcelus3 and Lauren Henderson10, 1Division of Immunology, Boston Children's Hospital, Harvard Medical School, Boston, MA, 2Boston Children's Hospital, Georgetown, MA, 3Boston Children's Hospital, boston, MA, 4Boston Children’s Hospital, Boston, MA, 5Boston Children's Hospital, Brookline, MA, 6Boston Children's Hospital, Somerville, MA, 7Division of Immunology, Boston Children's Hospital, Boston, MA, 8Boston Children's Hospital, Newton, MA, 9Department of Otolaryngology & Communication Enhancement, Boston Children’s Hospital, Harvard Medical School, Boston, MA, 10Boston Children's Hospital, Watertown, MA

    Background/Purpose: T peripheral helper (Tph) cells accumulate in the joints of children with ANA+ oligoarticular juvenile idiopathic arthritis (oligo JIA) and may provide pathogenic help…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • …
  • 20
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology